SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2007. For the three months ended December 31, 2007, the Company reported a net loss of $128.0 million or $3.35 loss per share compared to a net loss of $14.7 million or $0.39 loss per share for the same period last year. For the year ended December 31, 2007, the Company had a net loss of $207.3 million, or $5.45 loss per share compared with a net loss of $107.2 million, or $2.84 loss per share in 2006. The increase in net loss is primarily the result of a one-time non-cash impairment charge of $94.0 million related to the write-off of the indiplon prepaid royalty during the fourth quarter of 2007. Additionally, the Company incurred a $6.9 million charge related to a severance program enacted in December 2007.
Revenues for the fourth quarter of 2007 were $0.5 million compared with $9.4 million for the same period last year. The Company recognized $0.5 million in license fee revenues during the fourth quarter of 2007 related to the licensing of the Japanese rights for indiplon to Dainippon Sumitomo Pharma Co. Ltd. (DSP). During the fourth quarter of 2006, the Company recognized license fee revenues arising from the Pfizer, Inc. (Pfizer) collaboration of $0.7 million. Additionally, the Company recognized milestones related to CRF drug candidate development under the GlaxoSmithKline (GSK) agreement of $8.0 million for the fourth quarter of 2006.
Revenues for the year ended December 31, 2007, were $1.2 million, compared with $39.2 million for 2006. The decrease in revenues for the year ended December 31, 2007 is primarily due to the cancellation of our col/p>
Total revenues 532 9,440 1,224 39,234
Research and development 24,340 18,608 81,985 97,678
Sales, general and
administrative 10,786 7,095 37,481 54,873
Prepaid Royalty Write-Off 94,000 - 94,000 -
Total operating expenses 129,126 25,703 213,466 152,551
Loss from operations (128,594) (16,263) (212,242) (113,317)
Other income and (expenses):
Interest income and
expense, net 616 1,543 4,814 6,576
Other income and
(expense), net 3 8 129 (464)
Total other income 619 1,551 4,943 6,112
Net loss $(127,975) $(14,712) $(207,299) $(107,205)
Net loss per common share:
Basic and diluted $(3.35) $(0.39) $(5.45) $(2.84)
Shares used in the calculation
of net loss per common share:
Basic and diluted 38,165 37,894 38,009 37,722
NEUROCRINE BIOSCIENCES, INC.
Condensed Consolidated Balance Sheets
December 31, December 31,
Cash, cash equivalents and
marketable securities $179,385 $182,604
Other current assets 3,563 11,054
Total current assets 182,948 193,658
Property and equipment, net 82,598 91,378
Prepaid royalty - 94,000
Other non-current assets 11,108 10,641
Total assets $276,654 $389,677
Current liabilities $29,907 $20,116
Long-term liabilities 128,050 54,845
Stockholders' equity 118,697 314,716
Total liabilities and
stockholders' equity $276,654 $389,677laboration agreement with Pfizer. The Company recognized $6.5 million and $6.6 million in the form of license fees and sponsored development funding, respectively under the Pfizer collaboration agreement for the year ended December 31, 2006. The sales force allowance earned under the collaboration agreement was $16.5 million for 2006. The Company also recognized milestones under the GSK collaboration agreement of $9.0 million during 2006.
Research and development expenses were $24.3 million in the fourth quarter of 2007 compared to $18.6 million for the fourth quarter of 2006, primarily resulting from severance costs of $4.9 million and higher external development costs related to the GnRH clinical program, offset by lower laboratory and personnel costs. For the year ended December 31, 2007, research and development expenses were $82.0 million compared to $97.7 million last year. This $15.7 million decrease in year-to-date research and development expenses is due to lower personnel and laboratory costs, a result of our staff reductions in 2006 and lower external development costs.
Sales, general and administrative expenses were $10.8 million for the fourth quarter 2007 compared with $7.1 million for the same period in 2006, a direct result of $2.0 million in severance costs incurred in 2007, and increased marketing activities in the fourth quarter of 2007. For the year ended December 31, 2007 sales, general and administrative expenditures totaled $37.5 million compared to $54.9 million in 2006. The decrease in expenses is primarily a result of our severance program enacted during the third quarter of 2006.
The Company's balance sheet at December 31, 2007 reflected total assets of $276.7 million including cash, cash equivalents, and marketable securities of $179.4 million, compared with balances at December 31, 2006 of $389.7 million and $182.6 million, respectively. The Company's cash reserves were replenished during the fourth quarter to beginning of year levels. This was achieved through receipt of the $20.0 million upfront license fee from DSP for licensing of indiplon in Japan, and the sale and leaseback of the Company's campus which netted approximately $61.0 million in cash.
Financial Guidance for 2008
Exclusive of any new partnering agreements, the Company expects to have a net loss of approximately $75 to $80 million for 2008, and the cash burn from ongoing operations in 2008 is expected to be approximately $65 to $70 million.
"As we begin 2008 we are focusing the Company's resources towards advancing our clinical pipeline, led by three Phase II programs. Our GnRH compound is now in two large Phase II studies and this important program, with its multiple disease targets, continues to progress in partnering discussions. Our CRF collaboration with GSK has multiple compounds in clinical development for both CNS and GI disorders. Additionally, our Urocortin 2 program is scheduled to complete its preclinical toxicology studies this year in order to continue its Phase II clinical program in acute decompensated heart failure. We look forward to moving these programs and our preclinical targets ahead this year," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences.
On December 12, 2007, we received an action letter from the FDA stating
that indiplon 5mg and 10mg capsules are Approvable (Approvable Letter). The
Approvable Letter did not raise any of the issues previously raised by the
FDA in the May 15, 2006 Approvable Letter.
The Approvable Letter spelled out the following new requirements:
-- An additional objective/subjective clinical trial in the elderly.
-- A safety study assessing the rates of adverse events occurring with
indiplon when compared to a marketed product.
-- A preclinical study to evaluate indiplon administration during the
third trimester of pregnancy.
The Company has an end of review meeting to discuss the contents of the Approvable Letter scheduled with the FDA during the first quarter of 2008. We will provide an update on the results of that FDA meeting during our first quarter 2008 earnings call.
The Company's clinical development group and corporate partners are
advancing its lead programs through development. Neurocrine scientists
continue to build the Company's pipeline and meet the Company-wide goal of
bringing one new compound into development each year.
GnRH Antagonists in Expanded Phase II Clinical Trials for Endometriosis
-- In mid December, we completed enrollment of patients in the 6-month
Phase IIb clinical trial with NBI-56418.
-- A new tablet formulation has been selected based upon optimal
manufacturing processes and tablet characteristics to be used in all
-- An additional Phase IIb clinical trial with the new formulation tablet
was initiated in 2007 utilizing clinical endpoints that incorporate
recent guidance from the FDA.
The Company has completed enrollment in a Phase IIb study in which 252 patients with endometriosis will be treated over a 6-month period. This multi-center, randomized, double-blind, study includes three treatment groups, with two doses of NBI-56418, 150 mg once a day and 75 mg twice daily, and an active comparator, Depo-Provera(R). In addition to confirming the effect of NBI-56418 on endometriosis symptoms, this study is designed primarily to assess the impact of longer term treatment on bone mineral density as measured by DXA scan at the conclusion of dosing and at 6-months and 12-months post-treatment. Topline results from the 6-month treatment period are expected in mid-2008. The study will continue after the treatment period for DXA scans and safety assessments. The 6-month results, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the FDA.
The Company is also conducting two additional randomized placebo controlled Phase II clinical trials in 2008. The clinical endpoints for both of these trials will be a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial will include our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial was initiated in late 2007 and is expected to enroll approximately 150 patients. The Company expects topline results from the first three months of treatment at the end of 2008 or early 2009. The second trial is a four arm comparator trial of two doses of NBI-56418, placebo or Leuprolide Depot. This trial will be conducted in Central/Eastern Europe and will begin enrollment in the first half of 2008. Topline data from this 3-month double-blind trial should be available in early 2009.
Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.
Partnership discussions are ongoing for our GnRH program.
Corticotropin Releasing Factor (CRF1) Receptor Antagonists in Mood
Disorders and IBS.
-- GSK has recently completed a Phase II "proof of concept" clinical trial
in social anxiety disorder (SocAD) with the first CRF antagonist
-- GSK has completed enrollment of patients in a second Phase II "proof of
concept" trial with 876008 in irritable bowel syndrome (IBS).
-- Additional lead compounds for depression and anxiety include 561679,
which has completed a Phase I multi-dose trial, and will be moving into
a Phase II depression trial in 2008; and 586529 which has started a
Phase I single escalating dose trial.
The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and IBS. GSK has completed the first Phase II "proof of concept" clinical trial with a lead CRF1 receptor antagonist compound, 876008, for SocAD and has completed recruiting for a Phase II "proof of concept" clinical trial in IBS.
In the first double-blind, randomized, placebo controlled, multiple dose study to evaluate the safety and efficacy of the CRF1 receptor antagonist compound in patients with SocAD no statistically significant differences were observed in the key efficacy endpoints between 876008 and placebo at 12 weeks. This study included more than 200 adult subjects and assessed efficacy, safety, tolerability and pharmacokinetics of the compound and the drug was generally well tolerated with no serious adverse events reported.
The second "proof of concept" trial is a Phase II double-blind, randomized, placebo controlled study to evaluate the safety and efficacy of 876008 in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial. Standard assessments of safety, tolerability and pharmacokinetics will be conducted. The clinical endpoints reflect change in symptom frequency and severity via validated scales for IBS and the data should be available in the second half of 2008.
GSK is advancing the second lead CRF1 receptor antagonist, 561679, into
a Phase II depression study later this year. GSK has also initiated a Phase
I single dose escalating clinical trial with 586529, an additional CRF1
receptor antagonist compound.
Urocortin 2 for congestive heart failure (CHF):
-- Initiation of longer term (up to 72 hours in duration) Phase II
clinical trials of urocortin 2 are awaiting additional preclinical
data. We have identified a preclinical formulation that allows for the
necessary preclinical work to be completed by the third quarter of
Selective Norepinephrine Reuptake Inhibitor (sNRI) for Neuropathic Pain
-- Neurocrine completed a Phase I clinical trial with sNRI for neuropathic
pain. The single ascending dose study in healthy volunteers
demonstrated that the drug was well tolerated and the pharmacokinetic
characteristics were suitable for clinical development. The Company
will not proceed into multi-dose Phase I clinical trials at this time
in order to focus resources on the GnRH program.
Conference Call and Webcast Today at 5:00 PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 1-800-862-9098, (US) or 785-424-1051 (International) using the conference ID: 7NBIX2. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com
If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-0520 (US) or 402-220-2653 (International) using the conference ID: 7NBIX2. The call will be archived for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, irritable bowel syndrome, endometriosis and CNS related disorders. Indiplon was licensed from DOV Pharmaceuticals in 1998. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com
In addition to historical facts, this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those indicated in the forward-looking statements are risks
and uncertainties associated with Neurocrine's business and finances in
general, as well as risks and uncertainties associated with the Company's
indiplon program, GnRH program, R & D pipeline and Company overall.
Specifically, the risks and uncertainties the Company faces with respect to
its indiplon program include, but are not limited to; risk that the Company
will not be able to address issues and or requests set forth in the
December 12, 2007 indiplon capsule action letter from the FDA in a timely
manner if at all; risk that the Company will not be able to address issues
and or requests set forth in the December 12, 2007 indiplon capsule action
letter from the FDA in a manner acceptable to the FDA if at all; the risk
that FDA may reject any future indiplon regulatory filings or find them
incomplete or insufficient; and risk that indiplon approval and subsequent
commercialization may be significantly or indefinitely delayed or never
accomplished. The Company also faces risks and uncertainties with respect
to the Company's GnRH program including risk that the Company's GnRH
clinical trials will fail to demonstrate that the Company's clinical
candidates are safe and effective; risk that the Company's GnRH clinical
candidates will not proceed to later stage clinical trials; risks
associated with the Company's dependence on corporate collaborators for
development, commercial manufacturing and marketing and sales activities.
In addition, the Company faces risks and uncertainties with respect to the
Company's R & D pipeline including risk that the Company' research stage
GnRH receptor antagonists, urocortin 2, CRF1 receptor antagonist, and sNRI
clinical candidates will not proceed to later stage clinical trials, risk
that the Company's research programs will not identify pre-clinical
candidates for further development. With respect to its pipeline overall,
the Company faces risk that it will be unable to raise additional funding
required to complete development of all of its product candidates; risk
relating to the Company's dependence on contract manufacturers for clinical
drug supply; risks associated with the Company's dependence on corporate
collaborators for commercial manufacturing and marketing and sales
activities; uncertainties relating to patent protection and intellectual
property rights of third parties; risks and uncertainties relating to
competitive products and technological changes that may limit demand for
the Company's products; and the other risks described in the Company's
report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for
the quarter ended September 30, 2007. Neurocrine undertakes no obligation
to update the statements contained in this press release after the date
NEUROCRINE BIOSCIENCES, INC.
Condensed Consolidated Statements of Operations
(in thousands, except for per share data)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
and development $19 $213 $139 $6,716
License fees and milestones 486 9,227 986 16,038
Sales force allowance - - - 16,480
Grant Revenue 27 - 99 -<
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved